Cargando…
Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis: Oxaliplatin in neoadjuvant treatment for rectal cancer
BACKGROUND: Neoadjuvant fluoropirimidine (5FU)-based chemoradiotherapy (CRT) has been considered the standard of care for locally advanced rectal cancer (LARC). Whether addition of oxaliplatin (OXP) will further improve clinical outcomes is still debated. We conducted a meta-analysis to evaluate the...
Autores principales: | De Felice, Francesca, Benevento, Ilaria, Magnante, Anna Lisa, Musio, Daniela, Bulzonetti, Nadia, Caiazzo, Rossella, Tombolini, Vincenzo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427623/ https://www.ncbi.nlm.nih.gov/pubmed/28499428 http://dx.doi.org/10.1186/s12885-017-3323-4 |
Ejemplares similares
-
Induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery in locally advanced rectal cancer: preliminary results of a phase II study
por: De Felice, Francesca, et al.
Publicado: (2018) -
Is There a Benefit of Oxaliplatin in Combination with Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer? An Updated Meta-Analysis
por: Des Guetz, Gaëtan, et al.
Publicado: (2021) -
Impact of age on efficacy of postoperative oxaliplatin-based chemotherapy in patients with rectal cancer after neoadjuvant chemoradiotherapy
por: Huang, Xuan-zhang, et al.
Publicado: (2016) -
Clinical predictive factors of pathologic complete response in locally advanced rectal cancer
por: De Felice, Francesca, et al.
Publicado: (2016) -
Total neoadjuvant treatment in locally advanced rectal cancer
por: De Felice, Francesca, et al.
Publicado: (2021)